Progression-free survival data from the phase 3 TROPION-Lung01 trial showed that datopotamab deruxtecan as treatment of metastatic non–small cell lung cancer crossed the threshold for statistical significance.
Jordyn Sava
Jordyn Sava is an editor for Targeted Oncology.
Articles by Jordyn Sava
The partial clinical hold on the TakeAim Leukemia trial exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been lifted.
The combination of botensilimab and balstilimab combination showed a survival benefit, regardless of RECIST 1.1 responses, among patients with metastatic, heavily pretreated, microsatellite stable colorectal cancer.
In an interview with Targeted Oncology, BJ Rimel, MD, discussed the rationale, methods, and design of this phase 2 study for patients with endometrial cancer.
The NDA for ready-to-dilute cyclophosphamide injection has been approved by the FDA for various types of cancers.
Data from an early access program and the eNRGy trial evaluating zenocutuzumab have led the FDA to grant the agent breakthrough designation for patients with NRG1 fusion-positive pancreatic cancer.
In an interview with Targeted Oncology, Yann-Alexandre Vano, MD, discussed the implications of the findings from the phase 2 BIONIKK trial of second-line treatment for patients with metastatic RCC.
In an interview with Targeted Oncology, Benjamin L. Schlechter, MD, discussed the potential benefit of TAC T cells for patients with solid tumors.
Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.
In an interview, Harry Erba, MD, PhD, compared ziftomenib with other Menin inhibitors and discussed data from the phase 1/2 trial evaluating the menin-KMT2A inhibitor in patients with AML.
In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.
A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.
A fast track designation has been granted by the FDA to quaratusugene ozeplasmid with atezolizumab for the treatment patients with extensive-stage small cell lung cancer.
Topline results from the EPCORE NHL-1 trial showed promising efficacy findings and no new safety signals with epcoritamab in a cohort of 128 patients with relapsed/refractory follicular lymphoma.
Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.
The National Comprehensive Cancer Network has updated its guidelines to include the recently approved T-cell engaging bispecific antibody epcoritamab for B-cell lymphomas.
In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Among patients with unresectable or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma, envafolimab generated positive efficacy data with a well-tolerated safety profile.
In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.
ADX-2191 will not be granted approval by the FDA due to the results of the phase 3 GUARD trial.
In an interview with Targeted Oncology, Soyoung Park, MD, discusses the criteria used for determining transplant eligibility and choosing between the different types of transplants for patients with cancer.
The phase 1 study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-253 monotherapy in patients with acute myeloid leukemias.
VEGFR inhibitors, mTOR inhibitors, and immune checkpoint inhibitors have been studied as adjuvant therapy for patients with RCC. However, conflicting data from phase 3 trials have left investigators unclear on what their role is.
Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.
The safety and efficacy of the combination of lifileucel and pembrolizumab is being assessed in the phase 3 TILVANCE-301 among patients with untreated, unresectable, or metastatic melanoma.
A time-based pathway to final analysis has been cleared by the FDA to evaluate the effect of uproleselan on relapsed/refractory acute myeloid leukemia.
Following a report of a serious grade 5 adverse event, the phase 1 PLAT-08 trial of SC-DARIC33 in pediatric patients with acute myeloid leukemia has been placed on hold
Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.
In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.
The FDA’s Oncologic Drugs Advisory Committee discussed the potential need for interpreting pharmacology data, using trial designs that compare multiple dosages, and safety and tolerability assessments to help determine the optimal doses of oncology drugs for pediatric patients.